How PF-07328948 is processed in people with and without reduced liver function

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 study gives a single oral dose of PF-07328948 to groups of adults with varying levels of liver function and to healthy volunteers, and keeps participants onsite for about six days for monitoring. Blood samples will be taken at scheduled times to measure drug levels and compare pharmacokinetic parameters between groups. Participants with hepatic impairment are categorized by Child-Pugh class (A, B, or C) and must have stable disease and medications before enrollment. The goal is to determine whether decreased liver function changes how PF-07328948 is absorbed, distributed, metabolized, or eliminated.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male or female of nonchildbearing potential, between the ages of 18 (inclusive) and 75 years, at the screening visit.
* Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
* BMI of 17.5 to 40.0 kg/m2 (inclusive), and a total body weight ≥45 kg (99 lb).
* Group 4 only: at screening, no clinically relevant abnormalities identified by a detailed medical history, physical exam, including blood pressure and pulse rate measurement, ECG and clinical laboratory tests.
* Group 4 only: no known or suspected hepatic impairment and meet the criteria based on screening laboratory liver function tests.
* Groups 1, 2 \& 3 only: stable hepatic impairment that meets criteria for Class A, B, or C of the Child-Pugh classification with no clinically significant change in disease status within 28 days before screening.
* Groups 1, 2 \& 3 only: stable concomitant medications for the management of individual participant's medical history.

Exclusion Criteria:

* Any condition possibly affecting drug absorption
* At screening, a positive result for HIV antibodies.
* Evidence of a prothrombotic state, including history of deep vein thrombosis, pulmonary embolism, or arterial thrombosis, or known genetic predisposition.
* Other medical or psychiatric condition or laboratory abnormality that may increase the risk of study participation or make the participant inappropriate for the study.
* Use of specific prohibited prior/concomitant therapies
* Use of an investigational product within 30 days or 5 half-lives (whichever longer).
* eGFR\<60 mL/min/1.73m2 at screening.
* A positive urine drug test at screening or admission to study clinic.
* At screening or admission to study clinic, a positive breath alcohol test.
* History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of screening.
* Group 4 only: evidence of chronic liver disease including history of hepatitis, hepatitis B, or hepatitis C.
* Group 4 only: screening ECG demonstrating QTcF interval \>450 ms or a QRS interval \>120 ms.
* Group 4 only: screening seated systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg
* Group 1, 2 \& 3 only: Hepatic carcinoma or hepatorenal syndrome or limited predicted life expectancy (defined as \<1 year in Groups 2 \& 3 and \<6 months for Group 1 only).
* Group 1, 2 \& 3 only: a diagnosis of hepatic dysfunction secondary to any acute ongoing hepatocellular process that is documented by medical history, physical exam, liver biopsy, hepatic ultrasound, CT scan, or MRI.
* Group 1, 2 \& 3 only: history of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers less than 4 weeks prior to screening.
* Group 1, 2 \& 3 only: signs of clinically active Grade 3 or 4 hepatic encephalopathy
* Groups 1, 2 \& 3 only: severe ascites and/or pleural effusion, except for those categorized in Group 4 who may be enrolled provided participant is medically stable, per the study doctor's judgment.
* Groups 1, 2 \& 3 only: previously received a kidney, liver, or heart transplant.
* Groups 1, 2, \& 3 only: screening ECG demonstrating a QTcF interval \>470 ms or a QRS interval \>120 ms.
* Groups 1, 2 \& 3 only: persistent severe, uncontrolled hypertension at screening, admission to study clinic, or pre-dose on Day 1.
* Groups 1, 2 \& 3 only: ALT or AST \>5x upper limit of normal on clinical laboratory tests at screening.

Where it's running

• Orange County Research Center
  Lake Forest, California, United States Recruiting
• Orlando Clinical Research Center
  Orlando, Florida, United States Recruiting
• Genesis Clinical Research, LLC
  Tampa, Florida, United States Recruiting

Study contacts

• Study coordinator: Pfizer CT.gov Call Center
• Email: ClinicalTrials.gov_Inquiries@pfizer.com
• Phone: 1-800-718-1021

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Casdatifan pharmacokinetics in moderate hepatic impairment vs normal liver function

  This study tests how a single dose of casdatifan behaves in people with moderate liver impairment compared to healthy individuals with normal liver function.

  Recruiting Phase 1 Arcus Biosciences, Inc. · San Antonio, Texas · NCT07751250

• How the medicine Atirmociclib behaves in people with healthy liver or with liver disease

  This study tests how atirmociclib is processed in the body and how safe it is for adults with normal liver function or with stable mild to severe liver disease.

  Recruiting at 3 sites Phase 1 Pfizer · Miami Lakes, Florida and 2 other locations · NCT07677358

• Treprostinil Palmitil Inhalation Powder: how liver function affects drug in a single-dose test

  This study tests how mild to severe liver impairment changes the amount of treprostinil palmitil and treprostinil in the body after one 80 mcg dose of TPIP in people with and without liver problems.

  Recruiting at 4 sites Phase 1 Insmed Incorporated · Lake Forest, California and 3 other locations · NCT07643155

• How liver impairment affects AZD9550 and AZD6234

  This trial will test how single subcutaneous doses of two investigational drugs, AZD9550 and AZD6234, are processed and tolerated in adults with moderate or severe liver impairment compared with matched healthy volunteers.

  Recruiting at 3 sites Phase 1 AstraZeneca · Chandler, Arizona and 3 other locations · NCT07546760

• How BI 3000202 behaves in the blood in people with and without liver problems

  This study tests how BI 3000202 moves through the body in healthy adults and adults with liver impairment.

  Recruiting Phase 1 Boehringer Ingelheim · San Antonio, Texas · NCT07486102

• Radiprodil for adults with liver impairment

  It will test whether a single 15 mg oral dose of radiprodil is processed differently and tolerated safely in adults with mild, moderate, or severe liver impairment compared with healthy adults.

  Recruiting at 2 sites Phase 1 GRIN Therapeutics, Inc. · DeSoto, Texas and 1 other locations · NCT07457229

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.